Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) CFO Keith Lamont Cummings sold 10,911 shares of the business’s stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $11.56, for a total transaction of $126,131.16. Following the sale, the chief financial officer now directly owns 282,115 shares in the company, valued at $3,261,249.40. The sale was disclosed in a legal filing with the SEC, which is available through this link.
Pliant Therapeutics Stock Up 2.0 %
Shares of PLRX stock opened at $12.75 on Monday. The company has a quick ratio of 16.12, a current ratio of 16.12 and a debt-to-equity ratio of 0.07. The firm’s 50-day moving average is $12.25 and its 200-day moving average is $14.49. Pliant Therapeutics, Inc. has a 52-week low of $10.29 and a 52-week high of $20.23.
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.02). As a group, equities research analysts forecast that Pliant Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the stock. Citigroup cut their price target on shares of Pliant Therapeutics from $45.00 to $44.00 and set a “buy” rating on the stock in a research report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of Pliant Therapeutics in a research report on Friday, June 7th. Oppenheimer boosted their price target on shares of Pliant Therapeutics from $47.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 7th. Royal Bank of Canada cut their price target on shares of Pliant Therapeutics from $54.00 to $45.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $38.00 price target on shares of Pliant Therapeutics in a research report on Tuesday, May 7th. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $45.38.
View Our Latest Report on PLRX
Pliant Therapeutics Company Profile
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.
Featured Stories
- Five stocks we like better than Pliant Therapeutics
- How to Use the MarketBeat Dividend Calculator
- Top 3 Defense Stocks That Should Be on Your Radar
- Stock Market Sectors: What Are They and How Many Are There?
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- Why is the Ex-Dividend Date Significant to Investors?
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.